Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative anti-cancer therapies. Founded in 2014 and headquartered in Taipei, the company is notable for its proprietary MITTA (minimally-invasive targeted tumor ablation) technology, which delivers treatments for various solid malignant tumors through intratumoral drug administration. Gongwin Biopharm’s leading product, PTS302, targets severe malignant airway obstructions in non-small cell lung cancer and has obtained marketing approval in China. The company’s pipeline also includes candidates under clinical investigation for liver cancer, adenoid cystic carcinoma, and malignant pleural effusion. In addition to its human oncology initiatives, Gongwin Biopharm develops veterinary therapies for treating malignant tumors in companion animals. Recognized by Taiwan’s Ministry of Economic Affairs as a “Biotech New Drug Company,” it plays an important role in advancing targeted cancer therapies and expanding the market for minimally invasive oncology treatments in Asia.